Skip to main content
. 2021 Mar 11;107(3):593–603. doi: 10.3324/haematol.2020.274456

Figure 3.

Figure 3.

Kaplan-Meier plots for time to first treatment of the genomic risk stratification within each category defined by the alternative technique. (A) Patients classified in each category based on total number of aberrations found by chromosome banding analysis (CBA): non-complex Karyotype (CK) (0-2 abnormalities [abn.]), low/intermediate-CK (3-4 abn.) or high-CK (≥5 abn.) are represented in different plots. Time to first treatment (TTFT) of genomic microarrays (GM) defined groups was assessed. Within non-CK and low/intermediate-CK, cases classified as high-GC (≥5 copy number abnormalities [CNA] by GM) showed a poor outcome. In the high-CK group, those low-GC patients did not display a better evolution while intermediate-GC cases showed an unexpected median TTFT of 22 months. (B) Each plot represents patients classified in each category based on total number of CNA detected by GM: low-GC (0-2 CNA), intermediate-GC (3-4 CNA) or high-GC (≥5 CNA). Within each subgroup, TTFT of CBA defined groups was assessed. Low-GC patients could be stratified in three risk categories when reclassified by CBA, while no significant differences were observed when intermediate-GC and high-GC subsets were reclassified.